Collegium Pharmaceutical Inc. (COLL)
Symbol Info
Listed Symbol COLL
Name Collegium Pharmaceutical Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $280,413,000
Latest Fiscal EPS $-1.20
Price Info
21 Day Moving Average $11.5198
21 Day EMA $11.512590
50 Day Moving Average $11.4283
50 Day EMA $11.536620
200 Day EMA $13.329520
200 Day Moving Average 13.528980
52 Week High $19.83
52 Week Low $10.01
52 Week Change $-30.728600
Alpha 0.017463
Beta 0.5183
Standard Deviation 0.272939
R2 0.004498
Periods 53
Share Information
10 Day Average Volume 285,119
20 Day Average Volume 302,851
30 Day Average Volume 300,743
50 Day Average Volume 274,232
Outstanding Shares 33,470,530
Float Shares 32,687,613
Percent Float 97.66%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 327
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 3,453,735
Institute Holdings Percent -
Institute Sold Previous 3 Months 3,619,269
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 1
Insider Holdings Percent 2.30%
Insider Sold Previous 3 Months 12
Insiders Shares Owned 782,917
Price Change
7 Day Price Change $0.1000004
7 Day Percent Change 0.86%
21 Day Price Change $0.1599999
21 Day Percent Change 1.38%
30 Day Price Change $-1.1800003
30 Day Percent Change -9.10%
Month To Date Price Change $0.3100
Month To Date Percent 2.70%
90 Day Price Change $0.360000
90 Day Percent Change 3.15%
Quarter To Date $0.310000
Quarter To Date Percent 2.70%
180 Day Price Change $-4.54
180 Day Percent Change -27.80%
200 Day Price Change $-3.38
200 Day Percent Change -22.28%
Year To Date $-5.38
Year To Date Percent -31.33%
Profile
Description Collegium Pharmaceutical Inc is a US-based specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. The company's product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.
Details
Issue Type CS
Market Cap $394,617,549
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 33,470,530
CEO Joseph J. Ciaffoni
Employees 266
Last Audit UQ
Classification
CIK 0001267565
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 100 Technology Center Drive
Stoughton, MA 2072
Website http://www.collegiumpharma.com
Facisimile
Telephone +1 781 713-3699
Email info@collegiumpharma.com
Key Ratios
Profitability
EBIT Margin -4.5
EBITDA Margin 14.7
Pre-Tax Profit Margin -
Profit Margin Cont -2.39
Gross Margin 40.80
Profit Margin TOT -2.39
Income Statements
Revenue $222,983,000
Revenue Per Share $6.6621
Revenue 3 Years $568.90
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $257,564,684
Price To Sales 1.769720
Price To Free Cash 8.500000
PE High Last 5 Years -
Price To Book 4.2
Price To Cash Flow 3.9
PE Low Last 5 Years -
Price To Tangible Book 7.3
Financial Strength
Total Debt To Equity 0.3
Int Coverage -1.5
Current Ratio 1.2
Leverage Ratio 1.2
Quick Ratio 1.2
Long Term Debt To Capital 0.19
Assets
Receivables Turnover 1.5
Invoice Turnover 18.10
Assets Turnover 0.20
Management Effectiveness
Return Assets -4.48
Return On Equity -25.91
Return On Capital -14.84
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
COLL
Collegium ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.